Life Days: Celebrating the Anniversary of Your Injury
By Codi Darnell April 5, 2022 There are 365 days in a year. Most of them are days that pass by without much thought – the date just a marker to keep us oriented in time. It’s a way to keep track of assignments, registration forms, deadlines and all the other things that make the […]
NervGen Presenting Interim Phase 1 Clinical Trial Data for NVG-291 at the 2022 American Academy of Neurology Annual Meeting
Human subjects now being enrolled in the second cohort of multiple ascending dose portion of the study NVG-291 dose administered in the first cohort is already above the highest corresponding dose found to be efficacious in animal models and is substantially higher than the lower effective doses where dramatic functional improvements were observed Vancouver, […]
NervGen Pharma to Present at 2022 Virtual Growth Conference Presented by Maxim Group / Engages Apaton Finance to Provide Investor Relations Services in Europe
Vancouver, Canada. March 23, 2022 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, will be presenting at the 2022 Virtual Growth Conference presented by Maxim Group, being held virtually on March 28-30, 2022. Paul Brennan, NervGen’s President […]
NervGen Pharma Receives Approval from Safety Review Committee to Proceed to Second Cohort in Multiple Ascending Dose Portion of Phase 1 Clinical Trial of NVG-291
The dose of NVG-291 in the first cohort is already above the highest corresponding dose that resulted in dramatic functional improvements in animal models Approval moves NervGen one step closer to Phase 1b/2 efficacy studies in Alzheimer’s disease, multiple sclerosis and spinal cord injury patients later in 2022 NervGen’s proprietary NVG-291, has been demonstrated in […]
NervGen Pharma Reports 2021 Year End Results and Provides Update on Phase 1 Study
Vancouver, Canada. February 28, 2022 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today reported its financial and operational results for the year ended December 31, 2021. “We have continued to make important progress […]
Fashion, Beauty and Disability – Seeking Style with MS Advocate Ardra Shephard
By Codi Darnell February 8, 2022 What does it mean to feel beautiful or fashionable? Most people have images in their minds that pop up when they think of fashion and beauty – an idea of style that fits neatly in a box that we try to contort ourselves into. We browse through racks of clothes […]
Five Things Emergency Department Staff Should Know About Spinal Cord Injury
By Codi Darnell January 25, 2022 Deciding to seek care at an emergency department isn’t usually a decision people make lightly. Who wants to sit around for hours in a lineup of assorted symptoms, drowning in the smells of bodily fluids vaguely masked by latex and isopropyl alcohol? Not most people. But heading to the […]
Stroke Onward: Bringing Awareness and Change to the Emotional Recovery of Stroke Patients
By Codi Darnell January 11, 2022 Recovery from a debilitating illness or injury often revolves around the physical logistics of life – How do you move around? How do you use the bathroom? How do you speak, write, eat? There is no doubt that these physical aspects of life are important, but they are only […]
NervGen Pharma Applauds President Biden Signing Defense Bill / Department of Defense now able to Move Forward on Brain Plasticity Research
Cincinnati, Ohio January 4, 2022 – NervGen Pharma Corp., through its subsidiary, NervGen US Inc., (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, applauds President Biden for signing the Fiscal Year 2022 National Defense Authorization Act (FY22 NDAA) into law on December […]
NervGen Pharma Receives Ethics Board Approval for Multiple Ascending Dose Portion of NVG-291 Phase 1 Trial
Phase 1 program supports plan to start clinical trials in H2 2022 for NervGen’s NVG-291 in spinal cord injury, multiple sclerosis and Alzheimer’s disease indications Screening of healthy volunteers has already started for the trial’s multiple ascending dose (MAD) portion In preclinical studies, NVG-291 has been shown to promote repair of nervous system damage […]